Akebia Q4 net loss $22.8M; expects Vafseo Q1 2025 revenue ~$10-11M

Akebia Therapeutics, Inc.

Total revenues Q4 $46.5M, down 17% YoY; Auryxia net revenue $44.4M vs $53.2M.
Net loss Q4 $22.8M vs net income $0.6M; FY2024 net loss $69.4M vs $51.9M.
Vafseo launch: shipments began Jan 9; >500 prescribers through Feb; Q1 revenue guidance $10-11M.
Cash $51.9M at Dec 31; post-year-end raised $18.4M ATM + $9.3M BlackRock; funded ≥2 years.
Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.